To include your compound in the COVID-19 Resource Center, submit it here.

Cobiprostone: Development discontinued

Sucampo discontinued development of cobiprostone following a pre-specified futility analysis of a double-blind, U.S. Phase IIa trial evaluating an oral spray

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE